Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE-Norway: Aspirin Discontinuation in Elderly CAD Patients
NCT07854795Phase 4Not yet recruiting
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Feb 2027
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in coronary artery disease (CAD) (2 arms), sponsored by Vestre Viken Hospital Trust. Primary endpoint: Hierarchical composite endpoint at 3 years. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07854795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854795.